What's the Problem?

In 2020, the total volume of anthropogenic mass matched the total amount of biomass globally, which means it matched everything that is alive on the planet. We can only expect that this number keeps increasing since it's key to solve humanity's systemic challenges. But we have to make sure that conquering the great challenges of humanity doesn’t extinguish the planet’s capacity to sustain life. The current way of biomanufacturing has provided humanity with innumerable solutions. Bioprocessing is the most efficient way to align human advancement with a thriving nature. Today we have a limited biologics manufacturing capacity. As demand grows for antibodies therapeutics and cell therapies (CAR-T, cells, etc). Also personalized cell therapies represent a new paradigm in production. The COVID-19 crisis exposed the scarcity of manufacturing infrastructure for the production of anti-COVID-19 Abs and vaccines. We need to address shortages in production of biologics. These shortages pose a significant threat, delaying, and in some cases even denying, critically needed care for patients. Preventing shortages remains a top priority for the FDA.